Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Bavencio Avelumab metastatic Merkel Cell Carcinoma (mMCC) Reimburse with clinical criteria and/or conditions Complete
Bavencio Avelumab Urothelial Carcinoma (UC) Reimburse with clinical criteria and/or conditions Complete
Beleodaq Belinostat Withdrawn
Benlysta belimumab Lupus nephritis Reimburse with clinical criteria and/or conditions Complete
Benlysta Belimumab Systemic lupus erythematosus Do not list Complete
Benlysta Belimumab systemic lupus erythematosus Do not reimburse Complete
Beovu brolucizumab Diabetic macular edema Reimburse with clinical criteria and/or conditions Complete
Beovu brolucizumab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete
Beqvez fidanacogene elaparvovec Hemophilia B Reimburse with clinical criteria and/or conditions Complete
Besponsa Inotuzumab Ozogamicin Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Complete